(Q34148283)

31 July 2017

title

Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder (English)

1 reference

31 July 2017

1 reference

Benedikt Amann

3

0 references

Eduard Vieta

object named as

Eduard Vieta

5

0 references

author name string

Dina Popovic

1

1 reference

31 July 2017

Maria Reinares

2

1 reference

31 July 2017

Manel Salamero

4

1 reference

31 July 2017

publication date

31 October 2010

1 reference

31 July 2017

1 reference

31 July 2017

volume

213

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

657-667

1 reference

Confidence intervals for the number needed to treat

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Meta-analysis, Simpson's paradox, and the number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Mood state at study entry as predictor of the polarity of relapse in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Compelling or irrelevant? Using number needed to treat can help decide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Clinical and therapeutic implications of predominant polarity in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

The number needed to treat: a clinically useful measure of treatment effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

ECNP consensus meeting. Bipolar depression. Nice, March 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Size of treatment effects and their importance to clinical research and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-010-2056-8

Selecting appropriate treatments for maintenance therapy for bipolar disorder.

21 January 2018

1 reference

12 December 2020

Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo

1 reference

12 December 2020

A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.

1 reference

12 December 2020

A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group

1 reference

12 December 2020

Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies

1 reference

12 December 2020

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

1 reference

12 December 2020

10.1007/S00213-010-2056-8

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1050409209

0 references

1 reference